Synaptogenix Inc. (SNPX)
2.18
0.00 (0.00%)
At close: Apr 16, 2025, 3:30 PM
0.00% (1D)
| Bid | 2.09 |
| Market Cap | 3.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.77M |
| EPS (ttm) | -10.99 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -0.33 |
| Analyst | Buy |
| Ask | 2.25 |
| Volume | 700 |
| Avg. Volume (20D) | 8,536 |
| Open | 2.19 |
| Previous Close | 2.18 |
| Day's Range | 2.18 - 2.18 |
| 52-Week Range | 1.84 - 5.38 |
| Beta | 1.30 |
About SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and N...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2020
Employees 4
Stock Exchange NASDAQ
Ticker Symbol SNPX
Website https://www.synaptogen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SNPX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 542.20% from the latest price.
Stock Forecasts3 months ago
+19.46%
Synaptogenix shares are trading higher after the c...
Unlock content with
Pro Subscription
